Press Release|Articles|May 15, 2025

Camber Pharmaceuticals Announces Addition of Temozolomide Capsules, USP

Camber Pharmaceuticals is excited to announce the addition of Temozolomide Capsules, USP to the portfolio.

Temozolomide Capsules, USP is an alkylating drug indicated for the treatment of adults with:

  • Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment
  • Anaplastic astrocytoma
  • Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma
  • Treatment of adults with refractory anaplastic astrocytoma

Temozolomide Capsules, USP are available in the following strengths and sizes:

  • 5 mg | 5 and 14 count
  • 20 mg | 5 and 14 count
  • 100 mg | 5 and 14 count
  • 140 mg | 5 and 14 count
  • 180 mg | 5 and 14 count
  • 250 mg | 5 count

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME